Lv51
1598 积分 2022-08-15 加入
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
1小时前
已完结
Preoperative Physiological Reserve and Pathological Response as Independent Predictors of Survival in Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy
24天前
已完结
KEYNOTE-355 — OS benefit now reported
29天前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
29天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
1个月前
已完结
Efficacy and safety of immunotherapy combined with chemotherapy in both neoadjuvant and adjuvant settings among triple-negative breast cancer: A meta-analysis of randomized clinical trials
1个月前
已完结
Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis
1个月前
已完结
PARP Inhibitors for Breast Cancer Treatment
1个月前
已完结
皖公网安备34019202002308
